Member Info for mulledwine

http://www.investegate.co.uk/Article.aspx?id=201104210700113145F

SVG Capital off to flying start Date: Thursday 21 Apr 2011 LONDON (ShareCast) - A sharp improvement in the share price of its biggest investment, Hugo Boss, contributed to a strong increase in the net asset value (NAV) of investment firm SVG Capital in the first quarter. Adjusted NAV at the end of March stood at £1,108m, an 11% increase on the year-end value, which stood at just below £1bn. NAV per share was 350.6p on a fully diluted basis. The investment value of its Hugo Boss stake rose £41.8m in the quarter to £206.6m, reflecting an increase in expected earnings as the company continues to benefit from a recovery in the markets in which it operates as well as an increase in the multiple applied in the valuation. The firm's second biggest holding, Galaxy Entertainment, was also buoyant, with the value of the stake rising £28.5m to £139.8m, driven by continued improvements in trading. The new Galaxy Macau resort, the group's Asian-themed integrated casino, hotel and leisure resort is scheduled to open on 15 May 2011, the company noted. SVG Capital paid cash calls of £3.0m and received distributions of £37.5m in the period. Total distributions included £10.4m in relation to the sale of one warehoused fund asset, which was agreed prior to the year-end, but did not complete until January 2011. At 31 March 2011, the group had cash balances of £9.5m and borrowings of £290.3m, taking the group's net borrowed position to £280.8m, or 26.6% of adjusted shareholders' funds.

Key investment portfolio highlights for the three months to 31 March 2011 include: · 9% total return on the investment portfolio; 7% in local currency · Continued strong earnings momentum, particularly in the Permira IV portfolio companies · On a like-for-like basis, weighted average net multiples used to value the portfolio are broadly in-line with December 2010 multiples

This statement is made in accordance with the UK Listing Authority's Disclosure and Transparency Rules and relates to the period from 1 January 2011 to 31 March 2011. SVG Capital reports 11% growth in NAV over the first quarter of 2011 Adjusted unaudited Net Asset Value at 31 March 2011 · 11% increase (£108.6m) in adjusted unaudited net asset value to £1,108.0 million - 350.6p per share fully diluted (including the Directors' unaudited December 2010 valuation of SVG Advisers and SVG Investment Managers of 16.9p) · Adjusted unaudited Shareholders' funds increased to £1,054.3 million - 333.7p per share fully diluted (excluding the Directors' unaudited December 2010 valuation of SVG Advisers and SVG Investment Mangers)

http://www.investegate.co.uk/Article.aspx?id=201104210700113159F

Any Pharma / medical guru's able to comment on this news...I will have a look through some journals but certainly sounds good

Im no expert on Bio's but this sounds very good news for TRX

Antony Odell, Managing Director of Tissue Regenix, commented: "The PUCPR is a world class centre in this field and Professor da Costa an internationally recognised cardiac surgeon. Alongside our existing relationship with our UK development partner, NHS Blood and Transplant, this long-term collaboration with the PUCPR and Professor da Costa is yet another example of Tissue Regenix's strategy of seeking to expand our product pipeline more rapidly and at minimum cost and development risk to the Company. The global heart valve market represents a major opportunity for Tissue Regenix, we look forward to commercializing the dCELL® Heart Valve and making this product available worldwide to surgeons and patients."

YORK, 21 April, 2011 - Tissue Regenix, the regenerative medical device company, announces that it has entered into a commercialisation and IP agreement with one of its long term clinical collaborators, the Pontifical Catholic University of Parana (PUCPR) and Cardioprotese Ltda (representing Professor da Costa), both based in Brazil, which will facilitate the Company's entry into the $1.0bn global tissue heart valve market. Under the terms of the agreement Tissue Regenix obtains exclusive worldwide commercialisation rights (excluding Brazil) to all data generated from over 8 years clinical use of decellularised human donor heart valves as heart valve replacements. The deal involves royalties but no upfront or milestone payments. Highlights The agreement gives Tissue Regenix exclusive worldwide rights (excluding Brazil) to the clinical data which will support commercialisation of "dCELL® Heart Valve" Tissue Regenix has obtained exclusive worldwide commercialization rights (excluding Brazil) to all future decellularised products as part of an agreed development plan which includes a decellularised version of a commercially available bioprosthetic heart valve, which has over 5 years of clinical data and has been implanted in over 1200 patients Tissue Regenix will also accelerate the development of new applications for its exciting product pipeline, which includes alternate applications for its patch product and the porcine dCELL® Heart Valve, in conjunction with PUCPR utilising their world class facilities in Brazil The global tissue heart valves market is expected to grow at a CAGR of 6% in the period 2009-2016, and is estimated to reach $1.430bn by 2016 (Global data report 2010). Surgical aortic valve replacement is the most common heart valve operation, accounting for 60-70% of all valve surgery in the elderly. Over 140 patients have been implanted with human donor heart valves (including over 40 aortic valves) decellularised using Tissue Regenix's dCELL® technology. Initially Tissue Regenix will work with their UK development partner to transfer the technology for use in the NHS and also commercialise it in the rest of the world (excluding Brazil) via a licensing programme to other tissue banks.

http://www.halifaxmarketwatch.co.uk/rns.cgi?username=&ac=&action=news&rns=1&view=full&story_id=4189248

Haydn Gardner, Chief Executive Officer of Rheochem Plc said: "I am very pleased to announce the completion of this Disposal. The Company is now focused purely on oil and gas exploration and production. The sale of the fluids business unlocks significant value for shareholders and allows us to meet our commitments on the Athena field through to first oil production which is expected later this year. A new website to showcase our oilfield assets is currently under construction and is expected to be operational shortly."

The following are the key terms of the Disposal Agreement: · The Company has disposed of all the shares it owns in the Drilling Fluids Subsidiaries. · The sale price for the Drilling Fluids Business is up to a maximum of A$45 million (approx £28 million). The sale price is subject to adjustment in certain circumstances. Further details of how the consideration will be paid are set out below. · Newpark will acquire the "Rheochem" name. The Company's name has now been changed to Lochard Energy Group Plc. · Newpark is not a related party of the Company, nor of any of the Company's directors.

http://www.investegate.co.uk/article.aspx?id=201104210736443337F&fe=1

Nigel Little, Chairman of Niche commented, "Niche's acquisition of a stake in Arar is a further step in the Company's strategy to create value through investments in Turkish oil and gas exploration and development opportunities. We have formed an excellent relationship with Arar over the past twelve months and believe their portfolio offers significant exploration upside potential and the opportunity to realise near term gas production. We are pleased with the support of Niche's strategy demonstrated by our investors and look forward to further developing the Company's investments."

Placing to raise £14m & Acquisition of 5% stake in Arar Petrol ve Gaz AUPAS & Further Investment in Oman Resources Highlights · Niche has raised gross funds of approximately £13m through a placing of 185,500,227 shares · Niche to acquire a 5% interest in Arar - Turkey's second largest petroleum licence holder · In addition to the gross proceeds of the placing, Arar Managing Director, Fatih Alpay, to invest £1m via a separate subscription · Further investment loan into Oman Resources to increase equity holding to 35.7% upon full conversion of loans Niche, the AIM listed investment company with interests in onshore gas exploration and development activities in Turkey, has conditionally raised gross funds of approximately £13m via a placing (the "Placing") with institutional and other investors of 185,500,227 new ordinary shares at 7 pence per share (the "Placing Shares").

http://www.investegate.co.uk/Article.aspx?id=201104210700123163F

Nigel Little, Chairman of Niche commented, "The Hatay Blocks offer the opportunity for near term gas production. Having previously estimated recoverable gas reserves from Block 4077 of 80 Bcf, Oman Resources now estimates that the combined gross recoverable gas reserves across the portfolio are in the region of 300-500 Bcf. Such reserves would make it a leading domestic supplier in Turkey, with potential gross production of 15-25 MMcf/d when all of the fields reach full production."

Update Re. Hatay Blocks, Turkey Niche, the AIM listed investment company with interests in onshore gas exploration and development activities in Turkey, announced on 25 March 2011 that Oman Resources, in which Niche holds loan notes convertible into a 35.7%, had agreed with Arar Petrol ve Gaz AUPAS ("the Operator") that it would enter into farm in agreements and joint operating agreements in respect of three exploration licences held by the Operator in the Hatay District of Turkey: AR/ARR 4396 ("Block 4396"), AR/ARR/4395 ("Block 4395") and AR/ARR4394 ("Block 4394") (together the "Hatay Blocks"). Niche is pleased to provide further information regarding the expected work programme on the Hatay Blocks, which are situated in the Iskenderun Basin, close to the Eastern Mediterranean Sea: Block 4396 The Operator recently completed drilling of Hamam-1 Exploration Well and is currently preparing to start commercial production tests. The Operator plans to drill two additional prospects, identified as Yesiltepe and Gazi, in 2011. A 30km pipeline tie-in to the main existing network is planned. A CNG bottling plant is under construction. First production of natural gas from Block 4396 is expected in Q2 2011 Block 4395 The Operator recently spudded the Kastal-1 Exploration Well to test the first of two prospects identified in Block 4395, targeting the Miocene sandstones of the Kizildere Fm. Drilling of the second prospect, Goz, is planned for later this year. A 20km pipeline tie-in to the main existing network is planned. First production of hydrocarbons from Block 4395 is expected in Q2 2011. A CNG bottling plant is planned to enable immediate commercial test production. Block 4394 The Operator plans to deepen the Ayseler-1 Exploration Well on Ayseler prospect, located on a rotated fault block bounded by two faults dipping to the southeast, in July 2011. A 30km pipeline tie-in to the main existing network is planned. First production of hydrocarbons from Block 4394 is expected in Q3 2011. A CNG bottling plant is planned to enable commercial test production from Cumalar-1A well. The total combined gross planned expenditures for the work programmes across the Hatay Blocks over the next two years is estimated to be approximately $34.4 million. The Company has commissioned Senergy to prepare a CPR on the Hatay Blocks and Block 4077, expected to be completed in May 2011.

Michael Laurier, CEO of Symphony, commented: "We are delighted that our Distribution Agreement has come into full effect and launched our venture into the US market. We look forward to further building the Symphony brand in this vital and exciting market as well as creating more opportunities to showcase our d2w and d2p additives."

US Distribution Agreement commences with material order of d2w Symphony Environmental Technologies Plc ("Symphony" or "Company"), the specialist in advanced plastics technologies including controlled life and anti-microbial products, is pleased to announce that its 25 year distribution agreement ("the agreement") with its US Distributor, as announced on 23 February 2011, has come into full effect, following the first order of material quantity of d2w by Timothy Murtaugh (T/A Symphony Environmental USA) (the "Distributor"). Following the implementation of the agreement, the Distributor will now exclusively distribute and market the Company's d2w and d2p additives in the USA. The agreement also appoints the Distributor as Symphony's non-exclusive distributor of certain agreed finished products. Symphony is continuing its nationwide public relations and marketing campaign in the US and will be evaluating the results achieved to date in due course. As previously stated, the campaign is being co-ordinated by Burson-Marsteller and focuses on building brand awareness and recognition of plastic products, incorporating d2w.